Category Clinical Ethics
Should Five More Kidneys Go To Market?
Barry Hoffmaster argues that the moral cost of commodifying kidneys for transplantation must be calculated before the health care costs can be considered.
You Can’t Unring a Bell
Aviva Goldberg suggests that while payment may increase the number of living kidney providers, this benefit may not outweigh the risks associated with commodification of the human body.
Government Policy on Heroin-Assisted Therapy
Deb Mazer argues that current government policy is being driven by more than evidence.
The SUPPORT Debate Continues
Alice Dreger reports and comments on the recent SUPPORT debate at the ASBH meeting in Atlanta.
The Trouble with Biological Insurance
Jennie Haw questions the marketing of private cord blood banking as Biological InsuranceTM
Impact Ethics 